WYOST is an FDA-approved medicine for people with bone metastases from breast cancer, prostate cancer, and other solid tumors; and for people with multiple myeloma.
Serious bone problems include a fracture (broken bone), spinal cord compression (pressure on your spinal cord), and the need for radiation or surgery to your bones.
Learn how biosimilars are as safe and effective as name-brand medicines.
A medicine that can help prevent serious bone problems
If you have cancer that has spread to your bones (also called “bone metastases”) or multiple myeloma, your bones may be weaker. Having weakened bones can put you at risk for serious bone problems.
WYOST helps prevent serious bone problems by blocking signals to the cells that break down bone.
If you are switching from Xgeva® to WYOST, you can expect:
WYOST has the same safety and effectiveness as Xgeva®—so you can expect the same results with WYOST that you’ve had with Xgeva®.
WYOST also has the same monthly dosing as Xgeva®.b This means you'll continue to get your shot once a month.
People taking WYOST have access to support services through Sandoz One Source including financial support options and treatment reminders. Learn more here.
aWYOST can also be used to treat adults and older children whose bones have stopped growing and who have giant cell tumor of bone that can’t be removed with surgery; who are at risk for severe complications if some of their tissue or part or all of an organ is removed; or those who have higher than normal levels of calcium in their blood due to certain types of cancer that do not respond to bisphosphonate therapy.
bPeople who are new to treatment with denosumab (the medicine in WYOST) may need 2 additional doses of WYOST in their first month of treatment. This means additional 120 mg doses on Days 8 and 15 of the first month of treatment for people with giant cell tumor of bone and/or hypercalcemia of malignancy.
aWYOST can also be used to treat adults and older children whose bones have stopped growing and who have giant cell tumor of bone that can’t be removed with surgery; who are at risk for severe complications if some of their tissue or part or all of an organ is removed; or those who have higher than normal levels of calcium in their blood due to certain types of cancer that do not respond to bisphosphonate therapy.
bPatients who are new to treatment with denosumab (the medicine in WYOST) may need 2 additional doses of WYOST in their first month of treatment. This means additional 120 mg doses on Days 8 and 15 of the first month of treatment for people with giant cell tumor of bone and/or hypercalcemia of malignancy.
to help prevent serious bone problems
WYOST is a shot given in your arm, upper thigh, or stomach. Taking WYOST does not involve an infusion
Your shots will be given by a healthcare professional once every 4 weeks
Your doctor may suggest taking vitamin D and calcium supplements before you start WYOST and/or during your treatment. This is to help make sure your blood calcium stays at a normal level
It is very important that you get your WYOST shots on time—even if you’re not experiencing symptoms of serious bone problems. WYOST works to help prevent these problems, but only if you take it every month.
>
Our helpful support services can help you start and complete your treatment with WYOST®
Sandoz One Source experts work behind the scenes with your doctor and their office to help navigate the insurance process.
Eligible, commercially insured people may pay as little as $0 for WYOST. Terms and Conditions apply.c
enroll today
cWYOST Co-pay Terms and Conditions: Limitations apply. Valid only for those with private commercial insurance. Prescription must be for an approved indication. Restrictions, including monthly and/or annual maximums may apply. Patient is responsible for any costs once program limit is reached. Program not valid (i) if prescription for WYOST is paid, in whole or in part, under Medicare (including Part D, even in the coverage gap), Medicaid, Medigap, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. It is a violation of the terms and conditions of this program to use it to enroll patients for the purposes of a copay accumulator or maximizer program. Sandoz reserves the right to take any appropriate action against any person or entity using the program in violation of the terms and conditions. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and US Territories (Puerto Rico, Guam, Northern Mariana Islands, and Virgin Islands). This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Co-pay program has no cash value. Additional terms and conditions may apply. Sandoz reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
In order for a biosimilar to be approved by the FDA, the company that makes the biosimilar must show that there are no meaningful differences between the biosimilar and the name-brand product. This means you can expect the same safety and effectiveness from a biosimilar that you've had with the name-brand product.
Though biosimilars and generics are not quite the same thing, you can think of biosimilars as a generic version of a name-brand product. Like generics, biosimilars deliver results that are as safe and effective as name-brand medicines.
If you have been prescribed WYOST, sign up to get appointment reminders via text.
WYOST (denosumab-bbdz) is a prescription medicine used to:
Do not take WYOST if you:
If you receive WYOST, you should not receive other denosumab products.
Severe jaw bone problems
(osteonecrosis)
Severe jaw bone
problems
may happen when you take denosumab products. Your
doctor
should examine your mouth before you start, and
while
you
are taking WYOST. Tell your dentist that you are
taking
WYOST. It is important for you to practice good
mouth
care
during treatment with WYOST. In studies of patients
with
bone involvement, the rate of severe jaw problems
was
higher
the longer they were being treated with
denosumab.
Unusual thigh bone
fracture
Unusual
thigh bone fracture has been reported with denosumab
products. Symptoms of a fracture include new or
unusual
pain
in your hip, groin, or thigh.
Risk of high calcium levels following
treatment
discontinuation in patients with giant cell
tumor of
bone and in patients who are still
growing
Patients with a type of
cancer
called giant cell tumor of bone and patients with
bones
that
are not fully matured are at a greater risk to
develop
high
blood calcium levels after they stop taking WYOST,
that
can
be serious.
Increased risk of broken bones in the spine
after
discontinuing WYOST
After your
treatment
with WYOST is stopped, your risk for breaking bones
in
your
spine can increase, especially if you have a history
of
risk
factors such as osteoporosis or prior fractures.
Possible harm to your unborn
baby
You
should
not become pregnant while taking WYOST. Tell your
doctor
right away if you are pregnant, plan to become
pregnant,
or
suspect you are pregnant. WYOST can harm your unborn
baby.
In patients with bone metastases from solid tumors receiving denosumab, the most common side effects were tiredness/weakness, low phosphate levels in your blood, and nausea. The most common serious side effect of denosumab was shortness of breath.
In multiple myeloma patients receiving denosumab, the most common side effects were diarrhea, nausea, low red blood cells, low blood platelets and calcium levels, back pain, swelling of the lower legs or hands, upper respiratory tract infection, rash, and headache. The most common serious adverse reaction in multiple myeloma patients was pneumonia.
In patients with giant cell tumor of bone receiving denosumab, the most common side effects were pain in the joints, back pain, pain in extremity, fatigue, headache, nausea, common cold, pain in the muscles and joints, toothache, vomiting, low phosphate levels, constipation, diarrhea, and cough. The most frequent serious adverse reactions were severe jaw bone problems, bone giant cell tumor, low red blood cells, pneumonia, and back pain. The most frequent adverse reactions resulting in discontinuation of denosumab was severe jaw bone problems. The adverse reaction profile appeared similar in skeletally mature adolescents and adults.
In patients with hypercalcemia of malignancy receiving denosumab, the most common side effects were nausea, shortness of breath, decreased appetite, headache, swelling of the lower legs or hands, vomiting, low red blood cells, constipation, and diarrhea. The following adverse reactions of Grade 3 or greater severity related to study therapy were reported on-study: fatigue and infection. Grade 3 laboratory abnormalities included low magnesium levels, low potassium levels, and low phosphate levels. No deaths on-study were related to denosumab therapy.
These are not all the possible side effects of WYOST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see full Prescribing Information for WYOST.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
All trademarks and trade names are the property of their respective owners.
